ArticleRenal failure2025
Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate AKI after cardiac surgery by facilitating miR-21-5p targeting TEAD1.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Umbilical Cord Mesenchymal Stem Cells and Wnt Pathway Modulation: A Novel Therapy for Liver Cirrhosis and Steatosis.Tissue engineering and regenerative medicine · 2026Article
- The Perspective of Using Ischemic Tolerance in Clinical Practice.Biomedicines · 2026Review
- Optimal strategies for umbilical cord mesenchymal stem cell-derived exosomes in acute kidney injury: a network meta-analysis in rat models.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) is a common complication of cardiac surgery. Human umbilical cord mesenchymal stem cell (hUCMSC)-derived exosomes affect tissue damage and repair, and miR-21-5p reduces apoptosis and inflammation. However, miR-21-5p's role in cardiac surgery remains unclear.
methodsKidney injury molecule (KIM-1), neutrophil gelatinase-associated lipid carrier protein (NGAL), serum creatinine, and blood urea nitrogen (BUN) levels were tested by enzyme-linked immunosorbent assay. hUCMSCs and exosomes were identified
resultsKIM-1, NGAL, serum creatinine, and BUN levels were increased and miR-21-5p expression was inhibited in AKI after cardiac surgery. In AKI after cardiac surgery, hUCMSCs-Exos inhibited apoptosis and pyroptosis and promoted viability
conclusionshUCMSCs-Exos protect against AKI by enhancing miR-21-5p/TEAD1 binding
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.